Supernus Pharmaceuticals Company Profile (NASDAQ:SUPN)

About Supernus Pharmaceuticals (NASDAQ:SUPN)

Supernus Pharmaceuticals logoSupernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company's neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Specialty & Advanced Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:SUPN
  • CUSIP: 86845910
  • Web: www.supernus.com
Capitalization:
  • Market Cap: $1.97727 billion
  • Outstanding Shares: 50,699,000
Average Prices:
  • 50 Day Moving Avg: $44.56
  • 200 Day Moving Avg: $37.95
  • 52 Week Range: $17.25 - $50.05
P/E:
  • Trailing P/E Ratio: 19.68
  • Foreward P/E Ratio: 23.49
  • P/E Growth: 1.40
Sales & Book Value:
  • Annual Revenue: $252.59 million
  • Price / Sales: 7.83
  • Book Value: $4.52 per share
  • Price / Book: 8.63
Profitability:
  • EBIDTA: $82.36 million
  • Net Margins: 41.10%
  • Return on Equity: 30.73%
  • Return on Assets: 19.48%
Debt:
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 1.94%
  • Quick Ratio: 1.74%
Misc:
  • Average Volume: 705,105 shs.
  • Beta: 1.3
  • Short Ratio: 7.53
 

Frequently Asked Questions for Supernus Pharmaceuticals (NASDAQ:SUPN)

What is Supernus Pharmaceuticals' stock symbol?

Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."

How were Supernus Pharmaceuticals' earnings last quarter?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) released its earnings results on Wednesday, August, 2nd. The company reported $0.32 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.24 by $0.08. The firm had revenue of $75.83 million for the quarter, compared to analysts' expectations of $68.54 million. Supernus Pharmaceuticals had a return on equity of 30.73% and a net margin of 41.10%. View Supernus Pharmaceuticals' Earnings History.

Where is Supernus Pharmaceuticals' stock going? Where will Supernus Pharmaceuticals' stock price be in 2017?

6 analysts have issued 1 year price targets for Supernus Pharmaceuticals' stock. Their forecasts range from $45.00 to $51.00. On average, they expect Supernus Pharmaceuticals' share price to reach $48.17 in the next year. View Analyst Ratings for Supernus Pharmaceuticals.

What are analysts saying about Supernus Pharmaceuticals stock?

Here are some recent quotes from research analysts about Supernus Pharmaceuticals stock:

  • 1. Cantor Fitzgerald analysts commented, "Interim look at SPN-810 Phase 3 program leads to elimination of the low dose. SUPN announced that an interim analysis of the ongoing Phase 3 trials (CHIME 1 and CHIME 2) in impulsive aggression (IA) resulted in the decision to discontinue the low dose arm, 18mg daily, and randomization of future clinical trial subjects to receive either placebo or 36mg per day." (9/19/2017)
  • 2. According to Zacks Investment Research, "Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. " (7/18/2017)
  • 3. Jefferies Group LLC analysts commented, "Following Monday's Zydus settlement, SUPN reached a similar agreement with TEVA on the Trokendi XR (TXR) patent challenge ' allowing generic entry starting January 2023. There is now much more certainty in SUPN's ability to maintain cash flows from 76% of its current epilepsy franchises at least through 2022 and another 24% through 2027 (OXR), bridging to the latestage pipeline, which should come online in 2020. Importantly, SUPN fits with our M&A thesis." (3/8/2017)

Who are some of Supernus Pharmaceuticals' key competitors?

Who are Supernus Pharmaceuticals' key executives?

Supernus Pharmaceuticals' management team includes the folowing people:

  • Charles W. Newhall III, Independent Chairman of the Board
  • Jack A. Khattar, President, Chief Executive Officer, Secretary, Director
  • Gregory S. Patrick, Chief Financial Officer, Vice President
  • Stefan K. F. Schwabe M.D. Ph.D., Executive Vice-President - Research and Development, Chief Medical Officer
  • Padmanabh P. Bhatt Ph.D., Senior Vice President - Intellectual Property, Chief Scientific Officer
  • Victor Vaughn, Senior Vice President - Sales and Marketing
  • Georges Gemayel Ph.D., Independent Director
  • Frederick M. Hudson CPA, Independent Director
  • William A. Nuerge, Independent Director
  • John M. Siebert Ph.D., Independent Director

Who owns Supernus Pharmaceuticals stock?

Supernus Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (13.31%), Vanguard Group Inc. (6.93%), Acadian Asset Management LLC (3.10%), Bank of New York Mellon Corp (3.08%), State Street Corp (2.76%) and Rice Hall James & Associates LLC (2.71%). Company insiders that own Supernus Pharmaceuticals stock include Gregory S Patrick, M James Barrett, Padmanabh P Bhatt and Stefan KF Schwabe. View Institutional Ownership Trends for Supernus Pharmaceuticals.

Who sold Supernus Pharmaceuticals stock? Who is selling Supernus Pharmaceuticals stock?

Supernus Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Falcon Point Capital LLC, Northpointe Capital LLC, BNP Paribas Arbitrage SA, Bank of New York Mellon Corp, Cornerstone Capital Management Holdings LLC., Fiera Capital Corp, Menta Capital LLC and Gotham Asset Management LLC. Company insiders that have sold Supernus Pharmaceuticals stock in the last year include Gregory S Patrick, Padmanabh P Bhatt and Stefan KF Schwabe. View Insider Buying and Selling for Supernus Pharmaceuticals.

Who bought Supernus Pharmaceuticals stock? Who is buying Supernus Pharmaceuticals stock?

Supernus Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Emerald Advisers Inc. PA, Emerald Mutual Fund Advisers Trust, Hodges Capital Management Inc., Rice Hall James & Associates LLC, Royal Bank of Canada, Mesirow Financial Investment Management Equity Management and Prudential Financial Inc.. View Insider Buying and Selling for Supernus Pharmaceuticals.

How do I buy Supernus Pharmaceuticals stock?

Shares of Supernus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Supernus Pharmaceuticals' stock price today?

One share of Supernus Pharmaceuticals stock can currently be purchased for approximately $39.00.


MarketBeat Community Rating for Supernus Pharmaceuticals (NASDAQ SUPN)
Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  216 (Vote Outperform)
Underperform Votes:  103 (Vote Underperform)
Total Votes:  319
MarketBeat's community ratings are surveys of what our community members think about Supernus Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Supernus Pharmaceuticals (NASDAQ:SUPN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $48.17 (23.50% upside)

Analysts' Ratings History for Supernus Pharmaceuticals (NASDAQ:SUPN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/21/2017Cowen and CompanyReiterated RatingBuy$50.00LowView Rating Details
9/20/2017Jefferies Group LLCReiterated RatingBuy$51.00HighView Rating Details
9/20/2017Janney Montgomery ScottReiterated RatingHold$47.00LowView Rating Details
9/19/2017Stifel NicolausDowngradeBuy -> Hold$47.00HighView Rating Details
9/19/2017Cantor FitzgeraldReiterated RatingBuy$49.00HighView Rating Details
9/8/2017Piper Jaffray CompaniesReiterated RatingHold$45.00MediumView Rating Details
7/18/2016Northland SecuritiesDowngradeOutperform -> Market Perform$24.00N/AView Rating Details
(Data available from 9/25/2015 forward)

Earnings

Earnings History for Supernus Pharmaceuticals (NASDAQ:SUPN)
Earnings by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)
Earnings History by Quarter for Supernus Pharmaceuticals (NASDAQ SUPN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2017Q2 2017$0.24$0.32$68.54 million$75.83 millionViewListenView Earnings Details
5/9/2017Q1 2017$0.22$0.19$57.91 million$57.58 millionViewListenView Earnings Details
8/2/2016Q2$0.13$0.18$49.67 million$50.40 millionViewListenView Earnings Details
5/3/2016Q1$0.09$0.08$45.33 million$43.00 millionViewListenView Earnings Details
3/2/2016Q4$0.06$0.14$42.93 million$42.70 millionViewListenView Earnings Details
11/3/2015Q315$0.02$0.08$37.93 million$38.60 millionViewListenView Earnings Details
8/5/2015Q215$0.02$0.03$34.07 million$35.10 millionViewListenView Earnings Details
5/5/2015$0.02$0.02$29.16 million$28.13 millionViewListenView Earnings Details
11/11/2014Q314$0.36$0.39$43.10 million$52.50 millionViewN/AView Earnings Details
8/11/2014Q214($0.16)$0.08$19.85 million$29.67 millionViewN/AView Earnings Details
5/12/2014Q114($0.41)($0.38)$9.94 million$9.00 millionViewN/AView Earnings Details
3/12/2014Q413($0.55)($0.65)$7.78 million$10.30 millionViewN/AView Earnings Details
11/12/2013Q313($0.67)($0.78)$2.54 million$1.26 millionViewListenView Earnings Details
8/13/2013Q2 2013($0.65)($0.89)$0.91 million$0.28 millionViewN/AView Earnings Details
11/7/2012Q312($0.62)($0.55)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)
2017 EPS Consensus Estimate: $0.97
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.16$0.24$0.20
Q2 20172$0.23$0.25$0.24
Q3 20172$0.27$0.29$0.28
Q4 20172$0.23$0.26$0.25
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Supernus Pharmaceuticals (NASDAQ:SUPN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Supernus Pharmaceuticals (NASDAQ:SUPN)
Insider Ownership Percentage: 6.70%
Institutional Ownership Percentage: 95.38%
Insider Trades by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)
Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)
Insider Trades by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/8/2017Gregory S. PatrickCFOSell50,000$47.60$2,380,000.00View SEC Filing  
9/8/2017Padmanabh P BhattSVPSell5,000$49.86$249,300.00View SEC Filing  
9/7/2017Stefan K.F. SchwabeInsiderSell95,000$46.59$4,426,050.00View SEC Filing  
8/16/2017Padmanabh P BhattVPSell3,709$45.23$167,758.07View SEC Filing  
7/12/2017Padmanabh P BhattVPSell3,735$44.90$167,701.50View SEC Filing  
6/23/2017Padmanabh P BhattVPSell2,556$44.90$114,764.40View SEC Filing  
6/2/2017Padmanabh P BhattVPSell10,000$39.86$398,600.00View SEC Filing  
5/26/2017Padmanabh P BhattVPSell2,500$35.90$89,750.00View SEC Filing  
5/25/2017Padmanabh P BhattVPSell5,500$34.90$191,950.00View SEC Filing  
4/24/2017Gregory S PatrickCFOSell54,000$32.37$1,747,980.00View SEC Filing  
4/24/2017Padmanabh P BhattVPSell11,806$32.59$384,757.54View SEC Filing  
9/16/2016Gregory S PatrickCFOSell2,000$25.00$50,000.00View SEC Filing  
7/14/2016Gregory S. PatrickCFOSell3,395$22.00$74,690.00View SEC Filing  
4/11/2016Padmanabh P BhattVPSell30,762$16.49$507,265.38View SEC Filing  
12/9/2015Padmanabh P. BhattVPSell14,238$14.90$212,146.20View SEC Filing  
12/8/2015M James BarrettDirectorSell212,970$14.56$3,100,843.20View SEC Filing  
11/25/2015M James BarrettDirectorSell16,179$16.35$264,526.65View SEC Filing  
11/18/2015M James BarrettDirectorSell93,000$16.61$1,544,730.00View SEC Filing  
11/16/2015M James BarrettDirectorSell119,650$16.24$1,943,116.00View SEC Filing  
11/4/2015Padmanabh P BhattVPSell5,000$19.90$99,500.00View SEC Filing  
7/16/2015Gregory S PatrickCFOSell6,217$20.00$124,340.00View SEC Filing  
7/13/2015Stefan K.F. SchwabeEVPSell1,950$19.23$37,498.50View SEC Filing  
6/17/2015M James BarrettDirectorSell111,881$16.39$1,833,729.59View SEC Filing  
6/17/2015Scott D SandellMajor ShareholderSell136,597$16.50$2,253,850.50View SEC Filing  
6/16/2015M James BarrettDirectorSell55,105$16.85$928,519.25View SEC Filing  
6/16/2015Scott D SandellMajor ShareholderSell95,437$16.92$1,614,794.04View SEC Filing  
6/12/2015Stefan K.F. SchwabeEVPSell2,051$18.27$37,471.77View SEC Filing  
6/11/2015Stefan K.F. SchwabeEVPSell3,631$16.39$59,512.09View SEC Filing  
3/24/2015Jones W BryanVPSell1,900$12.00$22,800.00View SEC Filing  
8/19/2013Padmanabh BhattVPSell2,285$8.21$18,759.85View SEC Filing  
3/22/2013Michael BighamDirectorBuy35,000$5.41$189,350.00View SEC Filing  
3/21/2013John M SiebertDirectorBuy3,000$5.50$16,500.00View SEC Filing  
3/15/2013Jack A KhattarCEOBuy10,000$6.15$61,500.00View SEC Filing  
3/14/2013Gregory S PatrickCFOBuy5,000$6.95$34,750.00View SEC Filing  
12/4/2012John M SiebertDirectorBuy7,000$8.14$56,980.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Supernus Pharmaceuticals (NASDAQ:SUPN)
Latest Headlines for Supernus Pharmaceuticals (NASDAQ:SUPN)
Source:
DateHeadline
americanbankingnews.com logoSupernus Pharmaceuticals' (SUPN) Buy Rating Reiterated at Cantor Fitzgerald
www.americanbankingnews.com - September 24 at 9:08 PM
finance.yahoo.com logoSupernus Pharmaceuticals Hits 80-Plus Relative Strength Rating Benchmark
finance.yahoo.com - September 23 at 9:29 AM
americanbankingnews.com logoSupernus Pharmaceuticals, Inc. (SUPN) Rating Reiterated by Cowen and Company
www.americanbankingnews.com - September 21 at 4:28 PM
americanbankingnews.com logoJanney Montgomery Scott Reaffirms Hold Rating for Supernus Pharmaceuticals, Inc. (SUPN)
www.americanbankingnews.com - September 20 at 6:24 PM
americanbankingnews.com logoSupernus Pharmaceuticals, Inc. (SUPN) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - September 20 at 5:46 PM
rttnews.com logoSupernus Pharmaceuticals Inc. (SUPN) Sank To A 3-Month Low
www.rttnews.com - September 20 at 9:39 AM
finance.yahoo.com logoWhy Supernus Pharmaceuticals' Shares Plummeted 23.4% Today
finance.yahoo.com - September 20 at 9:39 AM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Capricor Therapeutics and Supernus Pharmaceuticals
finance.yahoo.com - September 20 at 9:39 AM
americanbankingnews.com logoSupernus Pharmaceuticals Inc (SUPN) Downgraded to Hold at Stifel Nicolaus
www.americanbankingnews.com - September 20 at 12:46 AM
streetinsider.com logoSupernus Pharma (SUPN) Reports Update on SPN-810 Phase III Clinical Trials
www.streetinsider.com - September 19 at 8:11 AM
rttnews.com logoSupernus Pharmaceuticals Inc. (SUPN) Is Falling After Study Update
www.rttnews.com - September 19 at 8:11 AM
finance.yahoo.com logoSupernus Provides Update on SPN-810 Phase III Clinical Trials
finance.yahoo.com - September 19 at 8:11 AM
finance.yahoo.com logoSupernus shares decline on drug study change
finance.yahoo.com - September 19 at 8:11 AM
americanbankingnews.com logoComparing Supernus Pharmaceuticals (SUPN) and Its Rivals
www.americanbankingnews.com - September 17 at 8:30 PM
americanbankingnews.com logoSupernus Pharmaceuticals, Inc. (SUPN) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - September 16 at 4:54 PM
americanbankingnews.com logoZacks: Analysts Anticipate Supernus Pharmaceuticals, Inc. (SUPN) Will Announce Quarterly Sales of $77.74 Million
www.americanbankingnews.com - September 15 at 9:48 AM
americanbankingnews.com logoStefan K.F. Schwabe Sells 95,000 Shares of Supernus Pharmaceuticals, Inc. (SUPN) Stock
www.americanbankingnews.com - September 11 at 10:20 PM
americanbankingnews.com logoInsider Selling: Supernus Pharmaceuticals, Inc. (SUPN) CFO Sells 50,000 Shares of Stock
www.americanbankingnews.com - September 11 at 10:20 PM
americanbankingnews.com logoSupernus Pharmaceuticals, Inc. (SUPN) SVP Sells $249,300.00 in Stock
www.americanbankingnews.com - September 11 at 10:20 PM
americanbankingnews.com logoSupernus Pharmaceuticals, Inc. (SUPN) Given "Hold" Rating at Piper Jaffray Companies
www.americanbankingnews.com - September 9 at 3:06 PM
prnewswire.com logoTechnical Snapshots for These Generic Drugs Stocks -- Catalyst Pharma, Flexion Therapeutics, Supernus Pharma, and Lannett
www.prnewswire.com - September 5 at 8:55 AM
americanbankingnews.com logoReviewing Advanced Accelerator Applications (AAAP) and Supernus Pharmaceuticals (SUPN)
www.americanbankingnews.com - September 3 at 8:30 PM
americanbankingnews.com logoReviewing Supernus Pharmaceuticals (SUPN) & AbbVie (ABBV)
www.americanbankingnews.com - August 30 at 12:18 PM
americanbankingnews.com logoSupernus Pharmaceuticals, Inc. (SUPN) Expected to Announce Quarterly Sales of $77.74 Million
www.americanbankingnews.com - August 27 at 3:34 AM
americanbankingnews.com logo Brokerages Expect Supernus Pharmaceuticals Inc (SUPN) Will Announce Earnings of $0.27 Per Share
www.americanbankingnews.com - August 25 at 4:28 PM
seekingalpha.com logoIs Supernus Becoming The Leader In ADHD Non-Stimulants? - Seeking Alpha
seekingalpha.com - August 24 at 1:30 PM
americanbankingnews.com logoSupernus Pharmaceuticals, Inc. (SUPN) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - August 22 at 4:36 PM
americanbankingnews.com logoSupernus Pharmaceuticals, Inc. (SUPN) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - August 20 at 9:56 AM
bizjournals.com logoRockville's Supernus Pharmaceuticals wins patents dispute trial
www.bizjournals.com - August 19 at 7:54 AM
americanbankingnews.com logoContrasting AbbVie (ABBV) and Supernus Pharmaceuticals (SUPN)
www.americanbankingnews.com - August 19 at 6:34 AM
streetinsider.com logoForm 8-K SUPERNUS PHARMACEUTICALS For: Aug 15
www.streetinsider.com - August 18 at 7:36 AM
americanbankingnews.com logoPadmanabh P. Bhatt Sells 3,709 Shares of Supernus Pharmaceuticals, Inc. (SUPN) Stock
www.americanbankingnews.com - August 16 at 10:44 PM
finance.yahoo.com logoSupernus Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SUPN-US : August 15, 2017
finance.yahoo.com - August 16 at 7:54 AM
finance.yahoo.com logoSupernus Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SUPN) : August 15, 2017
finance.yahoo.com - August 16 at 7:54 AM
feeds.benzinga.com logoSupernus Defeats Second Generic Challenger to Oxtellar XR®
feeds.benzinga.com - August 15 at 5:23 PM
americanbankingnews.com logoAnalysts Set Expectations for Supernus Pharmaceuticals, Inc.'s Q4 2017 Earnings (SUPN)
www.americanbankingnews.com - August 14 at 6:20 AM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about Supernus Pharmaceuticals Inc.
finance.yahoo.com - August 10 at 8:25 AM
americanbankingnews.com logoFY2019 Earnings Forecast for Supernus Pharmaceuticals, Inc. Issued By Jefferies Group (NASDAQ:SUPN)
www.americanbankingnews.com - August 9 at 2:32 PM
americanbankingnews.com logoCantor Fitzgerald Analysts Lower Earnings Estimates for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
www.americanbankingnews.com - August 9 at 8:36 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Will Post Quarterly Sales of $76.19 Million
www.americanbankingnews.com - August 9 at 7:44 AM
americanbankingnews.com logoQ3 2017 EPS Estimates for Supernus Pharmaceuticals, Inc. Increased by Analyst (SUPN)
www.americanbankingnews.com - August 8 at 7:08 AM
americanbankingnews.com logoSupernus Pharmaceuticals, Inc. (SUPN) Expected to Announce Earnings of $0.26 Per Share
www.americanbankingnews.com - August 7 at 8:54 AM
americanbankingnews.com logoPiper Jaffray Companies Reiterates Neutral Rating for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
www.americanbankingnews.com - August 5 at 4:18 PM
seekingalpha.com logoSupernus Pharmaceuticals' (SUPN) CEO Jack Khattar on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 5 at 7:30 AM
americanbankingnews.com logoJefferies Group LLC Reaffirms "Buy" Rating for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
www.americanbankingnews.com - August 5 at 7:14 AM
globenewswire.com logoSupernus Announces Record Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 4 at 8:40 AM
finance.yahoo.com logoEdited Transcript of SUPN earnings conference call or presentation 3-Aug-17 1:00pm GMT
finance.yahoo.com - August 4 at 8:40 AM
americanbankingnews.com logoSupernus Pharmaceuticals, Inc. (SUPN) Issues Earnings Results
www.americanbankingnews.com - August 3 at 9:21 PM
finance.yahoo.com logoSupernus Announces Record Second Quarter 2017 Financial Results
finance.yahoo.com - August 3 at 7:40 AM
finance.yahoo.com logoSupernus tops Street 2Q forecasts
finance.yahoo.com - August 3 at 7:40 AM

Social

Chart

Supernus Pharmaceuticals (SUPN) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by MarketBeat.com Staff